Reviews in Urology Volume 21, No. 4 2019Contributors

Medical Editorimg1Herbert Lepor, MDKnown for his pioneering work in the surgical management of prostate cancer and the physiology and pharmacology of benign prostatic disorders, Dr. Lepor is cofounder of Reviews in Urology. He is Professor and Martin Spatz Chairperson of Urology and Professor of Pharmacology at New York University School of Medicine in New York, NY.Associate EditorsDavid M Albala, MDDr. Albala is Chief of Urology at Crouse Hospital in Syracuse, NY, and Medical Director for Associated Medical Professionals (a group of 29 urologists). He is considered a national and international authority in laparoscopic and robotic urologic surgery and has been an active teacher in this area for over 20 years. His research and clinical interests have focused on robotic urologic surgery. In addition, other clinical interests include minimally invasive treatment of benign prostatic hypertrophy and the use of fibrin sealants in surgery. Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Peña, Secretary of Transportation, on classified and unclassified public health-related issues.Ellen Shapiro, MD, FACS, FAAPProfessor and Director of Pediatric Urology at New York University School of Medicine, Dr. Shapiro is known for her contributions to pediatric urology, especially in the area of fetal bladder, prostate, and urethral development. She recently served on the American Urological Association Guideline Panel for Vesicoureteral Reflux.LUGPA Honorary EditorRichard G Harris, MDDr. Harris is a founding member and CEO of UroPartners, an integrated urology practice with more than 60 physicians. Dr. Harris has been a practicing urologist in Chicago for more than 30 years. Dr. Harris attended Washington University in St. Louis and the Chicago Medical School. He then completed his residency in general surgery and urology at Loyola University Medical Center in Chicago, and currently serves as the assistant clinical professor of urology. His main focus in urology is prostate cancer, specifically metastatic castrate resistant cancer.Contributing EditorsDean G Assimos, MDArie S Belldegrun, MD, FACSGordon A Brown, DO, FACOSBenjamin M Brucker, MDMichael B Chancellor, MDRaoul S Concepcion, MD, FACSSteven A Kaplan, MDVahan S Kassabian, MD, FRCS(C), FACSStacy Loeb, MDRandall B Meacham, MDJ Curtis Nickel, MD, FRCSCAlan M. Nieder, MDAlan W Partin, MD, PhDDavid F Penson, MD, MPHJacob Rajfer, MDClaus G Roehrborn, MD, FACSJonathan N Rubenstein, MD, FACSKevin M Slawin, MDMichael Williams, MDReviews in Urology Volume 21, No. 4ContributorsProstate Cancer AcademyCorrectionMastheadIntravesical Therapy for NMIBC—Are We Any Closer?Long-term Consequences of Medical Therapy for Benign Prostatic HyperplasiaImpact of Demographic Factors and Systemic Disease on Urinary Stone Risk ParametersProstate Cancer Academy 2019 Selected SummariesComplexities of Contemporary Bladder Cancer CareEmphysematous PyelonephritisNovel Clinical Trial to Improve the Quality of PSA Screening Decisions for Black MenUsing 17-OHP as Serum Biomarker to Monitor Therapy in Patients With Hypogonadotropic HypogonadismArchives